Hes1 attenuates type I IFN responses via VEGF-C and WDFY1

被引：0
|
作者：
Ning, F. [1 ]
Li, X. [1 ]
Yu, L. [1 ]
Zhang, B. [1 ]
Zhao, Y. [2 ]
Liu, Y. [3 ]
Zhao, B. [4 ]
Shang, Y. [2 ]
Hu, X. [1 ]
机构：
[1] Tsinghua Univ, Inst Immunol, Beijing, Peoples R China
[2] Shandong Agr Univ, Coll Vet Med, Tai An, Shandong, Peoples R China
[3] Wuhan Univ, Coll Life Sci, Wuhan, Hubei, Peoples R China
[4] Weill Cornell Med Coll, Dept Med, New York, NY USA
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2019年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P1382
引用
收藏
页码：679 / 680
页数：2
相关论文
共 50 条
  • [31] Influenza a virus antagonizes type I and type II interferon responses via SOCS1-dependent ubiquitination and degradation of JAK1
    Du, Yinping
    Yang, Fan
    Wang, Qiuxia
    Xu, Nuo
    Xie, Yizhang
    Chen, Sujuan
    Qin, Tao
    Peng, Daxin
    VIROLOGY JOURNAL, 2020, 17 (01)
  • [32] Functionally Distinct Effects of the C-Terminal Regions of IKKε and TBK1 on Type I IFN Production
    Nakatsu, Yuichiro
    Matsuoka, Mayumi
    Chang, Tsung-Hsien
    Otsuki, Noriyuki
    Noda, Masahiro
    Kimura, Hirokazu
    Sakai, Kouji
    Kato, Hiroshi
    Takeda, Makoto
    Kubota, Toru
    PLOS ONE, 2014, 9 (04):
  • [33] Induction of VEGF-C expression via mGluR5 in the lymph node metastases of oral cancer by the SDF-1/CXCR4 system
    Uchida, Daisuke
    Kuribayashi, Nobuyuki
    Tamatani, Tetsuya
    Nagai, Hirokazu
    Miyamoto, Youji
    CANCER RESEARCH, 2012, 72
  • [34] T-bet suppresses the IFN-gamma mediated induction of a T cell intrinsic type I IFN signature during T helper 1 responses
    Mikami, Yohei
    Davis, Fred
    Iwata, Shigeru
    Sun, Hong-Wei
    Stephen, Brooks R.
    Han-Yu, Shih
    Kawabe, Takeshi
    Jiang, Kan
    Jankovic, Dragana
    Sher, Alan
    Kanno, Yuka
    O'Shea, John J.
    CYTOKINE, 2017, 100 : 42 - 42
  • [35] PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
    Hodgins, Jonathan J.
    Abou-Hamad, John
    O'Dwyer, Colin Edward
    Hagerman, Ash
    Yakubovich, Edward
    Tanese de Souza, Christiano
    Marotel, Marie
    Buchler, Ariel
    Fadel, Saleh
    Park, Maria M.
    Fong-McMaster, Claire
    Crupi, Mathieu F.
    Makinson, Olivia Joan
    Kurdieh, Reem
    Rezaei, Reza
    Dhillon, Harkirat Singh
    Ilkow, Carolina S.
    Bell, John C.
    Harper, Mary-Ellen
    Rotstein, Benjamin H.
    Auer, Rebecca C.
    Vanderhyden, Barbara C.
    Sabourin, Luc A.
    Bourgeois-Daigneault, Marie-Claude
    Cook, David P.
    Ardolino, Michele
    JOURNAL OF EXPERIMENTAL MEDICINE, 2024, 221 (07):
  • [36] The Th1/Tfh-like biased responses elicited by the rASP-1 innate adjuvant are dependent on TRIF and Type I IFN receptor pathways
    George, Parakkal Jovvian
    Marches, Radu
    Nehar-Belaid, Djamel
    Banchereau, Jacques
    Lustigman, Sara
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [37] Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling
    Yeh, Yu-Wen
    Cheng, Ching-Chia
    Yang, Shu-Ting
    Tseng, Chi-Feng
    Chang, Ting-Yu
    Tsai, Sin-Ying
    Fu, Earl
    Chiang, Chien-Ping
    Liao, Li-Chuan
    Tsai, Pei-Wen
    Yu, Yung-Luen
    Su, Jen-Liang
    ONCOTARGET, 2017, 8 (03) : 5603 - 5618
  • [38] Herpes simplex virus 1 targets IRF7 via ICP0 to limit type I IFN induction
    David Shahnazaryan
    Rana Khalil
    Claire Wynne
    Caroline A. Jefferies
    Joan Ní Gabhann-Dromgoole
    Conor C. Murphy
    Scientific Reports, 10
  • [39] Herpes simplex virus 1 targets IRF7 via ICP0 to limit type I IFN induction
    Shahnazaryan, David
    Khalil, Rana
    Wynne, Claire
    Jefferies, Caroline A.
    Gabhann-Dromgoole, Joan Ni
    Murphy, Conor C.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [40] shRNA-interfering LSD1 inhibits proliferation and invasion of gastric cancer cells via VEGF-C/PI3K/AKT signaling pathway
    Pan, Hong-Ming
    Lang, Wei-Ya
    Yao, Li-Jie
    Wang, Yan
    Li, Xiao-Ling
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (08) : 622 - 633
12345